ANI Pharmaceuticals ANIP Accumulated Depreciation
Accumulated Depreciation at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization.
The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about ANI Pharmaceuticals's accumulated depreciation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ANI Pharmaceuticals's accumulated depreciation?
- ANI Pharmaceuticals (ANIP) reported accumulated depreciation of $469.01M in Q1 2026.
- How has ANI Pharmaceuticals's accumulated depreciation changed year-over-year?
- ANI Pharmaceuticals's accumulated depreciation increased by 20.7% year-over-year, from $388.5M to $469.01M.
- What is the long-term trend for ANI Pharmaceuticals's accumulated depreciation?
- Over 5 years (2020 to 2025), ANI Pharmaceuticals's accumulated depreciation has grown at a 91.4% compound annual growth rate (CAGR), from $17.53M to $450.35M.
- What does accumulated depreciation mean?
- Total accumulated depreciation on property, plant, and equipment since acquisition — represents the consumed portion of asset useful lives.